Cytosorbents CorpCTSO
Market Cap: $56.1M
About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Employees: 186
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 49 [Q1] → 49 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3.23% less ownership
Funds ownership: 33.8% [Q1] → 30.57% (-3.23%) [Q2]
30% less capital invested
Capital invested by funds: $16.8M [Q1] → $11.7M (-$5.02M) [Q2]
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 871%upside $10 | Buy Maintained | 14 Aug 2024 |
HC Wainwright & Co. Sean Lee 25% 1-year accuracy 5 / 20 met price target | 3%downside $1 | Neutral Reiterated | 14 Aug 2024 |
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 871%upside $10 | Buy Initiated | 29 Jul 2024 |
Financial journalist opinion
Based on 5 articles about CTSO published over the past 30 days